Lanfos250 mg

Lanfos 250 mg is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD).

The recommended initial total daily dose of Lanfos 250 mg is 1,500 mg in divided doses. Titrate every 2 to 3 weeks based on serum phosphate level. Take Lanfos 250 mg with or immediately after meals.Lanfos 250 mg Chewable Tablets: Do not swallow tablets whole. Chew or crush tablet completely before swallowing.

Drugs Binding to Antacids: There is a potential for Lanfos 250 mg to interact with compounds which bind to cationic antacids (i.e., aluminum-,magnesium-, or calcium-based); therefore, do not administer such compounds within 2 hours of dosing with Lanfos 250 mg.Quinolone Antibiotics: Co-administration of Lanfos 250 mg with quinolone antibiotics may reduce the extent of their absorption. The bioavailability of oral ciprofloxacin was decreased by approximately 50% when taken with Lanfos 250 mg in a single-dose study in healthy volunteers. Administer oral quinolone antibiotics at least 1 hour before or 4 hours after Lanfos 250 mg. When oral quinolones are given for short courses, consider eliminating the doses of Lanfos 250 mg that would normally be scheduled near the time of quinolone intake to improve quinolone absorption.Levothyroxine: the bioavailability of levothyroxine was decreased by approximately 40% when taken together with Lanfos 250 mg. Administer thyroid hormone replacement therapy at least 2 hours before or 2 hours after dosing with Lanfos 250 mg and monitor thyroid stimulating hormone (TSH).

Contraindicated in bowel obstruction, including ileus and fecal impaction.

The most common adverse reactions for Lanfos 250 mg were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing. The following adverse reactions have been identified during post-approval use of Lanfos 250 mg constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet.

Gastrointestinal Adverse Effects: Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation, and fecal impaction have been reported in patients taking Lanthanum, some requiring surgery or hospitalization. During treatment with Lanfos 250 mg, physicians and patients should remain vigilant for signs and symptoms of gastrointestinal disorders, especially constipation and abdominal pain/distention, which may indicate bowel obstruction, ileus, or subileus. Treatment with Lanfos 250 mg should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal signs and symptoms. Advise patients who are prescribed Lanfos 250 mg Chewable Tablets to chew the tablet completely and not to swallow them whole. Serious gastrointestinal complications have been reported in association with unchewed or incompletely chewed tablets.

The symptoms associated with overdose are adverse reactions such as headache, nausea and vomiting. In clinical trials in healthy adults, gastrointestinal (Gl) symptoms were reported with daily doses up to 6,000 mg/day of Lanfos 250 mg administered with food.

Store in a cool (below 30° C) and dry place, away from light. Keep out of the reach of children.

Drugs used in chronic kidney dialysis

Lanfos 250 mg is a phosphate binder that reduces absorption of phosphate by forming insoluble Lanthanum phosphate complexes that pass through the Gl tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.In vitro studies have shown that Lanthanum binds phosphate in the physiologically relevant pH range of 3 to 7. In simulated gastric fluid, Lanthanum binds approximately 97% of the available phosphate at pH 3-5 and 67% at pH 7, when Lanthanum is present in a two-fold molar excess to phosphate. Bile acids have not been shown to affect the phosphate binding affinity of Lanthanum. In order to bind dietary phosphate, Lanfos 250 mg must be administered with or immediately after meals.

Pregnancy: Available data from case reports with use of Lanfos 250 mg in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Use a non-Lanthanum containing phosphate binder in a pregnant woman.Lactation: There are no data on the presence of Lanfos 250 mg from Lanfos 250 mg in human milk, the effects on the breastfed infant, or the effects on milk production. Use a non-Lanthanum containing phosphate binder in a lactating woman.

Pediatric Use: The safety and efficacy of Lanfos 250 mg in pediatric patients have not been established. The use of Lanfos 250 mg in this population is not recommended.Geriatric Use: Of the total number of patients in clinical studies of Lanfos 250 mg, 32% (538) were >65 years of age, while 9.3% (159) were >75 years of age. No overall differences in safety or effectiveness were observed between patients >65 years of age and younger patients.